English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1386]
News [2583]
Articles [24]
Editorials [0]
Conferences [149]
elearning [15]
Genomic profiling of penile squamous cell carcinoma reveals major biomarkers...
Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy
Genomic profiling of penile squamous cell carcinoma reveals major biomarkers for efficacy of immunotherapy ( Prof Andrea Necchi -  The Vita-Salute San Raffaele University, Milan, Italy )
23 Feb 2023
Pembrolizumab shows notable antitumour activity for patients with high-risk...
Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy
Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer ( Prof Andrea Necchi -  The Vita-Salute San Raffaele University, Milan, Italy )
23 Feb 2023
Plasma miR371 detects MRD and early relapse of germ cell tumours
Dr Lucia Nappi - University of British Columbia, Vancouver, Canada
Plasma miR371 detects MRD and early relapse of germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )
19 Feb 2023
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...
Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )
18 Feb 2023
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023
Nivolumab and salvage nivolumab plus ipilimumab for aRCC
Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center...
Nivolumab and salvage nivolumab plus ipilimumab for aRCC ( Prof Michael Atkins - Georgetown Lombardi Comprehensive Cancer Center, Georgetown, USA )
18 Feb 2023
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...
Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...
Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023
Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC
Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA
Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC ( Prof Scott Tagawa - Weill Cornell Medicine, New York City, USA )
18 Feb 2023
Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive...
Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA
Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations ( Prof Siamak Daneshmand - University of Southern California, Los Angeles, USA )
18 Feb 2023
Cell-free utDNA may predict transurethral resection of bladder tumour pathology...
Dr Kyle Rose - Moffitt Cancer Center, Florida, USA
Cell-free utDNA may predict transurethral resection of bladder tumour pathology in non–muscle invasive bladder cancer ( Dr Kyle Rose - Moffitt Cancer Center, Florida, USA )
18 Feb 2023
IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem...
Prof Aristotelis Bamias - University of Athens, Athens, Greece
IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC ( Prof Aristotelis Bamias - University of Athens, Athens, Greece )
18 Feb 2023
<1...1718192021...116>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top